June 2016 | Volume 15 | Issue 6 | Feature | 794 | Copyright © 2016
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from the manufacturers, plus reports from physicians who wish to share their clinical experience with these new products. In addition, we will inform our readers about the latest drugs receiving Food and Drug Administration (FDA) approval.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Dr. Perry Robins, JDD Editor-in-Chief and Mohs Surgery Pioneer, Joins Emerald Medical Applications
Emerald Medical Applications Corp., the Israeli-based company engaged in the development and sale of DermaCompare, its proprietary artificial intelligence technology and application for the early diagnosis of melanoma and other skin cancers, announced that Dr. Perry Robins has joined the Company's Medical Advisory Board.
Dr. Robins is Professor Emeritus of Dermatology and was Chief of the Mohs Micrographic Surgery Unit at New York University Medical Center for over forty years. He has performed more than 47,000 Mohs surgical procedures, and trained doctors from around the world. He is also the Founder and President of The Skin Cancer Foundation, an international organization dedicated to skin cancer awareness, research, and public and medical education.